Vcanbio Cell & Gene Engineering Corp., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 394.17 million compared to CNY 366.68 million a year ago. Revenue was CNY 394.17 million compared to CNY 366.68 million a year ago. Net income was CNY 35.82 million compared to CNY 45.55 million a year ago. Basic earnings per share from continuing operations was CNY 0.08 compared to CNY 0.1 a year ago. Diluted earnings per share from continuing operations was CNY 0.08 compared to CNY 0.1 a year ago.